Employees: 1001-5000
Founded date: 1987
Investors 1
| Date | Name | Website |
| - | Baring Pri... | bpepindia.... |
Mentions in press and media 11
| Date | Title | Description |
| 25.02.2026 | SteinCares and Shilpa Biologicals Strike into Licensing Agreement to Expand Access to Biosimilars Across Latin America | New partnership combines Shilpa Biologicals' development and manufacturing capabilities with SteinCares' regional commercialization platform Collaboration aims to expand patient access to cost-effective treatments and reinforces SteinCares'... |
| 11.11.2025 | Shilpa Pharma Lifesciences Awarded EcoVadis Gold Medal for Outstanding Sustainability Practices | RAICHUR, India, Nov. 11, 2025 /PRNewswire/ -- Shilpa Pharma Lifesciences Limited, a material subsidiary of Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED), has been awarded the prestigious Gold Medal by EcoVadis, the world's most tru... |
| 11.11.2025 | Shilpa Medicare Announces Positive Phase 3 Results for OERIS™ -- A Novel Once-Weekly Ondansetron Extended-Release Injection for Chemotherapy-Induced Nausea and Vomiting (CINV) | Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections RAICHUR, India, Nov. 11, 2025 /PRNewswire/ -- Shilpa Medicare Limite... |
| 14.08.2025 | Shilpa Medicare's NorUDCA Makes History as First Approved NAFLD Therapy Worldwide | Shilpa Medicare emerges as the global pioneer to receive approval for NorUDCA, offering new hope to over a billion people affected by Non-Alcoholic Fatty Liver Disease (NAFLD) NAFLD affects 1 in 4 people globally (1.2 billion), with 188 mil... |
| 04.08.2025 | Alveolus Bio Secures Strategic Investment from Shilpa Medicare to Advance Groundbreaking Pulmonary Therapeutics | Shilpa Medicare Serves as Lead Investor, Positioning Alveolus Bio for Phase 2 Clinical Trials and First-in-Human Studies CAMBRIDGE, Mass. and BIRMINGHAM, Ala. and RAICHUR, India, Aug. 4, 2025 /PRNewswire/ -- Alveolus Bio, a pioneering respi... |
| 04.08.2025 | - | Shilpa Medicare Serves as Lead Investor, Positioning Alveolus Bio for Phase 2 Clinical Trials and First-in-Human Studies CAMBRIDGE, Mass. and BIRMINGHAM, Ala. and RAICHUR, India, Aug. 4, 2025 /PRNewswire/ -- Alveolus Bio, a pioneering respi... |
| 12.03.2025 | Shilpa Medicare Secures SEC-CDSCO Nod for Nor-Ursodeoxycholic Acid Tablets, Eyes Market Launch for NASH | RAICHUR, India , March 12, 2025 /PRNewswire/ -- Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED), a leading API and formulation manufacturer, announces that the Subject Expert Committee (SEC) of CDSCO has approved its Investigational ... |
| 30.08.2024 | Shilpa Medicare's Breakthrough: A New Dawn for Recombinant Human Albumin | In a world where medical supply chains often resemble a game of Jenga, one company has just pulled out a crucial block without toppling the tower. Shilpa Medicare Limited, based in Raichur, India, has made history by completing the first Ph... |
| 28.08.2024 | Shilpa Medicare Makes History: First Indian Company Completes Phase 1 Trial for Recombinant Human Albumin (rHA) 20% | RAICHUR, India, Aug. 28, 2024 /PRNewswire/ -- In a major breakthrough, Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED) proudly announces the successful completion of its Phase 1 clinical trial for its flagship product, sRbumin® - rec... |
| 28.08.2024 | Shilpa Medicare Makes History: First Indian Company Completes Phase 1 Trial for Recombinant Human Albumin (rHA) 20% | RAICHUR, India, Aug. 28, 2024 /PRNewswire/ -- In a major breakthrough, Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED) proudly announces the successful completion of its Phase 1 clinical trial for its flagship product, sRbumin® - rec... |
Show more